Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Random

Display 15 Products per page

Sutent
Read More
Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and FLT3.
March 6, 2019
Find out more
Epclusa
Read More
Epclusa ([sofosbuvir + velpatasvir]; Gilead) is a once-daily, fixed-dose combination of Gilead’s nucleotide NS5B polymerase inhibitor, sofosbuvir; and the company’s second-generation NS5A inhibitor, velpatasvir.
November 6, 2017
Find out more
Sorilux
Read More
Following its 2010 launch, Sorilux (calcipotriene; Stiefel/GlaxoSmithKline) has experienced slow

uptake in the psoriasis market, despite having the financial support of GlaxoSmithKline. This comes as

no surprise as the US psoriasis market is saturated with several types of established calcipotriene

formulations, limiting Sorilux’s uptake.
August 26, 2016
Find out more
Idalopirdine
Read More
Idalopirdine (Lundbeck/Otsuka) is an active, potent, and selective oral 5-hydroxytryptamine-6 receptor antagonist.
September 2, 2016
Find out more
Trogarzo
Read More
Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics) is a recombinant humanized monoclonal antibody approved for the treatment of HIV-1 infection. It targets the HIV-1 post-attachment process by binding one of the domains of the CD-4 protein, which inhibits a conformational change in CD-4 that is necessary to allow entry of HIV into T-cells.
July 28, 2019
Find out more
Jardiance
Read More
Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor originally developed by Boehringer Ingelheim for the treatment of type 2 diabetes.
February 27, 2019
Find out more
Aspirin
Read More
Aspirin (acetylsalicylic acid) is a non-steroidal anti-inflammatory drug (NSAID) and antiplatelet that is taken orally and commonly used for the treatment of pain. It is highly genericized and has been available in its present form since 1899, when it was first marketed by Bayer.
July 2, 2018
Find out more
ALKS 3831
Read More
ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes.
April 9, 2018
Find out more
Pyridorin
Read More
Pyridorin’s (pyridoxamine; NephroGenex) trial program has been put on hold due to company finances

and lack of investor/partner interest, so could well be suspended.
April 15, 2016
Find out more
Zafatek
Read More
Zafatek (trelagliptin; Takeda) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.
November 7, 2017
Find out more
Galvus
Read More
Galvus (vildagliptin; Novartis) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.
November 7, 2017
Find out more
GS-5745
Read More
GS-5745 (Gilead) is a humanized monoclonal antibody designed to selectively target the matrix metalloproteinase-9 (MMP9) enzyme. MMP9 plays a key role in the regulation of processes.
July 21, 2016
Find out more
Epogen
Read More
Epogen is an ESA administered by intravenous or subcutaneous injection, and is indicated for the treatment of CIA.
January 11, 2018
Find out more
Opdivo
Read More
Opdivo is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells.
September 9, 2019
Find out more
Mavyret
Read More
Mavyret ([glecaprevir + pibrentasvir]) is AbbVie’s next-generation, pan-genotypic regimen, which is positioned as a replacement for the Viekira Pak franchise ([paritaprevir + ritonavir + ombitasvir] ± dasabuvir) and is intended to reverse the company’s hepatitis C revenue decline. Mavyret is forecasted to achieve greater commercial success than its predecessor, and will allow AbbVie to quickly recoup the genotype 1/4 (GT-1/4) patient share lost to Zepatier ([grazoprevir + elbasvir]; Merck & Co) during 2016–17 because of its more attractive eight-week dosing schedule in non-cirrhotic patients, as well as AbbVie’s anticipated willingness to discount heavily to achieve uptake.
November 6, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *